Pathology Department, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom.
Maelor Academic Unite (MAU), Betsi Cadwaladr University Health Board, Wrexham, United Kingdom.
Br J Biomed Sci. 2023 Sep 26;80:11573. doi: 10.3389/bjbs.2023.11573. eCollection 2023.
B-Cell Lymphoproliferative Disorders (B-LPDs) are a group of heterogenous disorders characterised by the accumulation of B-cells in peripheral blood, bone marrow, lymph nodes and spleen. They have a variable disease course and outcome and many share similar features making differential diagnosis challenging. Therefore, accurate diagnosis is fundamental in particular for determining treatment options. Immunophenotyping by flow cytometry plays a crucial role in the diagnosis of B-LPDs. However, overlapping immunophenotyping patterns exist and the use of novel monoclonal antibodies has become increasingly important in immunophenotyping analysis. More recently differential expression of CD200 has been reported in various B-LPDs and that CD200 may improve the differentiation between chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). In this study CD200 expression is evaluated in different B-LPDs. A total of 100 samples were collected and analysed by immunophenotyping flow cytometry over a period of 1 year (2017-2018), by a panel of monoclonal antibodies including CD200. The percentage of CD200 and its expression intensity was evaluated and compared between different groups of B-LPDs. All of the 50 cases of CLL expressed CD200 with moderate to bright intensity, 6 MCL cases lacked the expression of CD200. Furthermore, all 5 cases of hairy cell leukaemia (HCL) expressed CD200. Out of all B-LPDs evaluated, CD200 expression in HCL cases was noted to be the brightest. The other 39 cases were not found to be B-LPDs. CD200 has an important role in differentiating CLL from MCL, HCL has a consistent bright expression of CD200. By adding CD200 to the combinations of markers in routine testing panel, Immunophenotyping by flow cytometry can be an effective tool in the diagnosis of B-LPDs especially in cases with atypical immunophenotyping pattern. Our result support that CD200 can be added to routine testing panel as it is useful in differentiating them.
B 细胞淋巴增殖性疾病(B-LPDs)是一组异质性疾病,其特征是外周血、骨髓、淋巴结和脾脏中 B 细胞的积累。它们的疾病过程和结果各不相同,许多疾病具有相似的特征,这使得鉴别诊断具有挑战性。因此,准确的诊断对于确定治疗方案尤为重要。流式细胞术免疫表型分析在 B-LPDs 的诊断中起着至关重要的作用。然而,免疫表型存在重叠模式,新型单克隆抗体的使用在免疫表型分析中变得越来越重要。最近,人们报道了 CD200 在各种 B-LPDs 中的差异表达,并且 CD200 可能有助于区分慢性淋巴细胞白血病(CLL)和套细胞淋巴瘤(MCL)。在这项研究中,评估了 CD200 在不同 B-LPDs 中的表达。在 1 年(2017-2018 年)期间,通过包括 CD200 在内的一组单克隆抗体,对总共 100 例样本进行了免疫表型流式细胞术分析。评估了不同 B-LPD 组之间 CD200 的百分比及其表达强度,并进行了比较。所有 50 例 CLL 病例均表达 CD200,强度为中等到明亮,6 例 MCL 病例缺乏 CD200 的表达。此外,所有 5 例毛细胞白血病(HCL)病例均表达 CD200。在所评估的所有 B-LPDs 中,HCL 病例的 CD200 表达最为明亮。其他 39 例则未被发现为 B-LPDs。CD200 在区分 CLL 和 MCL 方面具有重要作用,HCL 则持续强烈表达 CD200。通过在常规检测面板中添加 CD200 作为标志物组合,可以使流式细胞术免疫表型分析成为诊断 B-LPDs 的有效工具,特别是在免疫表型不典型的病例中。我们的研究结果支持将 CD200 添加到常规检测面板中,因为它有助于鉴别诊断。